FDA
-
-
-
-
-
-
-
Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
-
-
-
-
-
-
-
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
-
-
-
-
-
-
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
-
-
-
-
-
-
Piper Sandler Downgrades Capricor Therapeutics (CAPR) to Neutral
-
-
-
-
-
-
-
Capricor disputes FDA briefing materials ahead of deramiocel review
-
-
-
-
-
-
-
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
-
330,685 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

